📊 BTMD Key Takeaways
Investment Thesis
Biote Corp demonstrates concerning financial distress with negative stockholders' equity of -$58.5M despite generating positive operating cash flows and profitability. The company's debt burden ($103.1M) significantly exceeds total assets, creating unsustainable leverage that threatens long-term viability even as current operations remain marginally profitable.
BTMD Strengths
- Strong operating margins at 18.5% with net margins of 14.1% indicate profitable core operations
- Positive free cash flow of $30.2M (15.7% FCF margin) demonstrates ability to generate cash from operations
- Healthy ROA of 25.1% shows efficient asset utilization relative to profitability
BTMD Risks
- Negative stockholders' equity of -$58.5M indicates severe balance sheet insolvency and technical bankruptcy
- Long-term debt of $103.1M exceeds total assets of $107.6M, creating dangerous leverage ratios
- Revenue declining 2.5% YoY combined with negative equity suggests deteriorating competitive position unable to support debt load
- Quick ratio of 0.79x indicates potential liquidity strain on short-term obligations
Key Metrics to Watch
- Stockholders' equity trajectory and debt restructuring efforts
- Operating cash flow sustainability and ability to service long-term debt
- Revenue stabilization and gross margin trends to assess operational health
BTMD Financial Metrics
💡 AI Analyst Insight
biote Corp. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BTMD Profitability Ratios
BTMD vs Default Sector
How biote Corp. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BTMD Balance Sheet & Liquidity
BTMD 5-Year Financial Trend
5-Year Trend Summary: biote Corp.'s revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.09 reflects profitable operations.
BTMD Growth Metrics (YoY)
BTMD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $48.0M | -$546.0K | $-0.02 |
| Q2 2025 | $48.9M | $3.2M | $0.10 |
| Q1 2025 | $46.8M | -$4.2M | $-0.12 |
| Q3 2024 | $45.6M | -$546.0K | $-0.02 |
| Q2 2024 | $49.2M | -$5.1M | $-0.19 |
| Q1 2024 | $44.8M | -$2.1M | $-0.06 |
| Q3 2023 | $42.0M | $15.0K | $0.00 |
| Q2 2023 | $41.4M | -$2.6M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BTMD Capital Allocation
BTMD SEC Filings
Access official SEC EDGAR filings for biote Corp. (CIK: 0001819253)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BTMD
What is the AI rating for BTMD?
biote Corp. (BTMD) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BTMD's key strengths?
Strong operating margins at 18.5% with net margins of 14.1% indicate profitable core operations. Positive free cash flow of $30.2M (15.7% FCF margin) demonstrates ability to generate cash from operations.
What are the risks of investing in BTMD?
Negative stockholders' equity of -$58.5M indicates severe balance sheet insolvency and technical bankruptcy. Long-term debt of $103.1M exceeds total assets of $107.6M, creating dangerous leverage ratios.
What is BTMD's revenue and growth?
biote Corp. reported revenue of $192.2M.
Does BTMD pay dividends?
biote Corp. pays dividends, with $1.7M distributed to shareholders in the trailing twelve months.
Where can I find BTMD SEC filings?
Official SEC filings for biote Corp. (CIK: 0001819253) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BTMD's EPS?
biote Corp. has a diluted EPS of $0.74.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.